High-Deductible Health Plans Linked to Delayed Diagnosis of Metastatic Cancer
Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.
Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.
Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.
The incidence of advanced lung cancer declined by 3 cases per 100,000 people per year in 2015-2018 relative to 2004-2014.
The overall response rate was 66.7%, and the median duration of response was 17.5 months.
Among patients with ER+/HER2+ breast cancer, the median survival after distant recurrence increased from 2.3 years in 2000 to 4.8 years in 2019.
Acupuncture was associated with improvements in symptoms and quality of life.
Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes.
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Rivoceranib produced responses whether or not patients had received prior treatment with a VEGFR TKI.
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.